| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 122 | / | 2013 | ||||||||
| Date of issue: | 2013-09-12 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Current report 122 buy back 12092013 | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| SOPHARMA AD (the “Company") hereby informs that from 5 September 2013 up to and including 11 September 2013 the Company bought 2300 own shares representing 0.0017 % of the share capital of the Company, to the total value of 7 516.30 BGN on the Bulgarian Stock Exchange. The average price per share was 3.27 BGN. The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 215 717, representing 3.95% of the share capital of the Company. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 122 buy back 12092013.doc | Current report 122 buy back 12092013 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2013-09-12 | Ognian Donev | Executive Director | |||
